Patents by Inventor Christoph T. ELLEBRECHT

Christoph T. ELLEBRECHT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods of muscle specific kinase chimeric autoantibody receptor cells
    Patent number: 11905321
    Abstract: The invention includes a chimeric autoantibody receptor (CAAR) specific for anti-muscle-specific kinase (MuSK) B cell receptor (BCR), compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells comprising the CAAR.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: February 20, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Aimee S. Payne, Christoph T. Ellebrecht, Sangwook Oh, Michael C. Milone
  • COMPOSITIONS AND METHODS OF CHIMERIC AUTOANTIBODY RECEPTOR T CELLS
    Publication number: 20230303653
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.
    Type: Application
    Filed: January 19, 2023
    Publication date: September 28, 2023
    Inventors: Aimee S. PAYNE, Christoph T. ELLEBRECHT, Vijay BHOJ, Michael C. MILONE
  • COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION
    Publication number: 20230071283
    Abstract: Provided herein are fusion proteins including two protein domains separated by a heterologous protease cleavage site, wherein a first of the protein domains is a conditional expression domain. Thus, the fusion proteins comprise three essential elements: a conditional expression domain, a domain containing the protein of interest, and a protease cleavage domain separating the two. Also provided herein are methods for treating autoantibody and alloantibody-mediated diseases or conditions in a subject by targeting B cells with anti-B cell modified T cells. In one embodiment, a chimeric antigen receptor (CAR) modified T cell is selectively ablated in a subject after adoptive transfer. Pharmaceutical compositions comprising the temporally regulated CAR modified T cell are also described herein.
    Type: Application
    Filed: April 14, 2017
    Publication date: March 9, 2023
    Inventors: Andrei Golosov, Carla Patricia Pinto Guimaraes, Gregory Motz, Michael C. Milone, Christoph T. Ellebrecht, Aimee S. Payne
  • Compositions and methods of chimeric autoantibody receptor T cells
    Patent number: 11578113
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: February 14, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Aimee S. Payne, Christoph T. Ellebrecht, Vijay Bhoj, Michael C. Milone
  • Compositions and methods of chimeric autoantibody receptor T cells
    Patent number: 11407803
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: August 9, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Aimee S. Payne, Christoph T. Ellebrecht, Vijay Bhoj, Michael C. Milone
  • Compositions and methods of chimeric autoantibody receptor T cells
    Patent number: 11407804
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: August 9, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Aimee S. Payne, Christoph T. Ellebrecht, Vijay Bhoj, Michael C. Milone
  • Compositions and methods of chimeric autoantibody receptor T cells
    Patent number: 11407802
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: August 9, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Aimee S. Payne, Christoph T. Ellebrecht, Vijay Bhoj, Michael C. Milone
  • COMPOSITIONS AND METHODS FOR TREATING MELANOMA WITH A CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20210161958
    Abstract: The present invention includes compositions and methods for using a chimeric antigen receptor that specifically binds to melanocortin receptor (MCR). The present invention relates generally to the treatment of a patient having cancer that expresses one or more melanocortin receptors (MCR), such as melanoma. The invention also includes methods of making a genetically modified T cell expressing a chimeric antigen receptors (CAR) that binds to MCR.
    Type: Application
    Filed: April 17, 2019
    Publication date: June 3, 2021
    Inventors: Todd Ridky, Christopher Natale, Aimee S. Payne, Christoph T. Ellebrecht
  • Method of Redirecting T Cells to Treat HIV Infection
    Publication number: 20200362012
    Abstract: The present invention relates to compositions and methods for treating of a HIV infected mammal using a CD4 membrane-bound chimeric receptor or a HIV specific scFvs CARs. One aspect includes a modified T cell and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with HIV infection.
    Type: Application
    Filed: August 7, 2020
    Publication date: November 19, 2020
    Inventors: James L. Riley, Rachel Leibman, Aimee S. Payne, Christoph T. Ellebrecht, Michael C. Milone
  • COMPOSITIONS AND METHODS FOR TARGETING GAMMA DELTA T CELLS WITH CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20200339687
    Abstract: The invention includes compositions comprising a chimeric antigen receptor (CAR) specific for an GD T Cell receptor (anti-GD TCR CAR), vectors comprising the same, compositions comprising anti-GD TCR CAR vectors packaged in viral particles, and recombinant T cells or other effector cells comprising the anti-GD TCR CAR of the invention. The invention also includes methods of making a genetically modified T cell expressing an anti-GD TCR CAR wherein the expressed CAR comprises an extracellular domain that binds to GD T cells or to cells expressing a GD TCR.
    Type: Application
    Filed: January 18, 2019
    Publication date: October 29, 2020
    Inventors: Aimee S. Payne, Christoph T. Ellebrecht
  • Method of redirecting T cells to treat HIV infection
    Patent number: 10738099
    Abstract: The present invention relates to compositions and methods for treating of a HIV infected mammal using a CD4 membrane-bound chimeric receptor or a HIV specific scFvs CARs. One aspect includes a modified T cell and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with HIV infection.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: August 11, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James L. Riley, Rachel Leibman, Aimee S. Payne, Christoph T. Ellebrecht, Michael C. Milone
  • COMPOSITIONS AND METHODS OF MUSCLE SPECIFIC KINASE CHIMERIC AUTOANTIBODY RECEPTOR CELLS
    Publication number: 20190375817
    Abstract: The invention includes a chimeric autoantibody receptor (CAAR) specific for anti-muscle-specific kinase (MuSK) B cell receptor (BCR), compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells comprising the CAAR.
    Type: Application
    Filed: June 4, 2019
    Publication date: December 12, 2019
    Inventors: Aimee S. Payne, Christoph T. Ellebrecht, Sangwook Oh, Michael C. Milone
  • COMPOSITIONS AND METHODS OF CHIMERIC AUTOANTIBODY RECEPTOR T CELLS
    Publication number: 20190315829
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.
    Type: Application
    Filed: April 22, 2019
    Publication date: October 17, 2019
    Inventors: Aimee S. Payne, Christoph T. Ellebrecht, Vijay Bhoj, Michael C. Milone
  • COMPOSITIONS AND METHODS OF CHIMERIC AUTOANTIBODY RECEPTOR T CELLS
    Publication number: 20190315830
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.
    Type: Application
    Filed: April 22, 2019
    Publication date: October 17, 2019
    Inventors: Aimee S. PAYNE, Christoph T. ELLEBRECHT, Vijay BHOJ, Michael C. MILONE
  • COMPOSITIONS AND METHODS OF CHIMERIC AUTOANTIBODY RECEPTOR T CELLS
    Publication number: 20190315831
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.
    Type: Application
    Filed: April 22, 2019
    Publication date: October 17, 2019
    Inventors: Aimee S. PAYNE, Christoph T. ELLEBRECHT, Vijay BHOJ, Michael C. MILONE
  • COMPOSITIONS AND METHODS OF CHIMERIC AUTOANTIBODY RECEPTOR T CELLS
    Publication number: 20190309041
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.
    Type: Application
    Filed: April 19, 2019
    Publication date: October 10, 2019
    Inventors: Aimee S. PAYNE, Christoph T. ELLEBRECHT, Vijay BHOJ, Michael C. MILONE
  • Compositions and methods of chimeric autoantibody receptor T cells
    Patent number: 10301370
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: May 28, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Aimee S. Payne, Christoph T. Ellebrecht, Vijay Bhoj, Michael C. Milone
  • Method of Redirecting T Cells to Treat HIV Infection
    Publication number: 20180265565
    Abstract: The present invention relates to compositions and methods for treating of a HIV infected mammal using a CD4 membrane-bound chimeric receptor or a HIV specific scFvs CARs. One aspect includes a modified T cell and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with HIV infection.
    Type: Application
    Filed: September 22, 2016
    Publication date: September 20, 2018
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: James L. Riley, Rachel Leibman, Aimee S. Payne, Christoph T. Ellebrecht, Michael C. Milone
  • COMPOSITIONS AND METHODS OF CHIMERIC AUTOANTIBODY RECEPTOR T CELLS
    Publication number: 20170051035
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.
    Type: Application
    Filed: May 1, 2015
    Publication date: February 23, 2017
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Aimee S. PAYNE, Christoph T. ELLEBRECHT, Vijay BHOJ, Michael C. MILONE